{
  "docId": "019de070-3b27-7318-9c92-a5817b78bd41",
  "docSlug": "ce86c4a3bf509aea21f24e2159890cb6",
  "documentTitle": "BioNTech | Results Presentation Deck | 28 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 28,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3b27-7318-9c92-a5817b78bd41/5",
  "deckHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41",
  "deckJsonHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41.json",
  "deckAnchorHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.07,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d44288c4-02ae-4f15-a9b3-2754cbb54702",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.83,
        "x": 0.13,
        "y": 0.68
      },
      "kind": "list",
      "text": "Strategic collaboration with Regeneron to conduct randomized Phase 2 trial with Libtayo and FixVac in Melanoma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37bde06b-ac54-4021-b3b4-b7c0fc096ddf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.83,
        "x": 0.13,
        "y": 0.42
      },
      "kind": "list",
      "text": "Published Phase 1 data and started recruiting for randomized Phase 2 trials of iNeST in adjuvant cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56fea264-6fc1-4dfe-a1b4-b26717fc2f76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.83,
        "x": 0.13,
        "y": 0.83
      },
      "kind": "list",
      "text": "Entered agreements for ~$1.1 billion in gross proceeds from non-dilutive payments and equity / debt financings in year to-date",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69ed0784-7be6-4f69-9516-eb9bfb0e7a7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.83,
        "x": 0.13,
        "y": 0.47
      },
      "kind": "list",
      "text": "First patient dosed in FIH Phase 1/2 trial of BNT411 small molecule TLR7 agonist",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a163a59-6017-450a-a4f2-1fedd7931d1e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.83,
        "x": 0.13,
        "y": 0.55
      },
      "kind": "list",
      "text": "Ongoing scale-up of mRNA manufacturing infrastructure and supply chain in Germany",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "937f6531-1132-452f-ad5f-54370622f4d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.83,
        "x": 0.13,
        "y": 0.2
      },
      "kind": "list",
      "text": "12 immunotherapies across 3 drug classes now in the clinic (mRNA, Antibodies, Small molecule)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ee46426-62fa-4fb7-a7b1-6e703badd1d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.83,
        "x": 0.13,
        "y": 0.28
      },
      "kind": "list",
      "text": "Initiated pivotal Phase 2b/3 trial for BNT162b2 COVID-19 vaccine; Commercial supply agreements signed for >250 million doses of BNT162 in 2020/21",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc8247c5-f1f6-49fc-b1e4-af45e369ccf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.26,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "Q2 2020 highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7912e7d7-5f63-4475-9d7a-319ac19a952e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "20124505-2820-462a-984f-e0180d5dd22d",
      "evidence": "list/bullet: Initiated pivotal Phase 2b/3 trial for BNT162b2 COVID-19 vaccine; Commercial supply agreements signed for >250 million doses of BNT162 in 2020/21",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "3f302383-efe4-4c44-9d20-f8e4f342005f",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Attention",
      "beatSlug": "monroes-sequence-attention",
      "evidence": "The presentation starts with an overview of Q2 2020 highlights and key messages",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}